
Russian-developed thymic bioregulator extract — restores immune function in immunosenescent patients. Decades of clinical use in Russian geriatrics.
Not in stock yet. Message us on WhatsApp and we'll let you know as soon as it arrives.
Ranges cited in research literature. Not a usage recommendation. For research use only.
Thymalin is a polypeptide complex extracted from calf thymus, developed by Vladimir Khavinson and Vyacheslav Morozov in Leningrad in the 1970s and registered in the USSR in 1982 as an immunomodulator. It is not a single peptide: it is a standardized fraction of low-molecular-weight peptides (1–10 kDa) defined by its extraction process, from which the synthetic dipeptide Thymogen (Glu-Trp) was later derived as an identifiable active principle. It is the founding product of the “peptide bioregulator” school.
Its proposed action is to restore thymic tissue function and, with it, the maturation and differentiation of T lymphocytes, normalizing the CD4/CD8 ratio and cytokine production in states of immunosenescence or immunosuppression. In animal models and in the original group's studies it improved cellular-immunity parameters in old animals and in radiation and chemotherapy models; the zinc–thymulin axis, central to thymic physiology, is often cited as the frame of reference.
Human evidence is extensive in number of publications but almost entirely Russian, from small cohorts and with methodological limitations; a Russian pilot trial in COVID-19 pneumonia exists from 2020. It holds no approval outside Russia and the Commonwealth of Independent States, and its animal origin implies lot-to-lot variability and biological-product considerations. Renova distributes it for research only.
| Class | Bovine thymic polypeptide complex (biological product, bioregulator) |
| Composition | 1–10 kDa peptide fraction from calf thymus; no single sequence · synthetic derivative: Thymogen (Glu-Trp) |
| Origin | Khavinson and Morozov, Leningrad, 1970s; Soviet registration 1982 |
| Proposed action | Restoration of thymic function; T-lymphocyte maturation; CD4/CD8 normalization |
| Models | Aged animals, radiation, chemotherapy; small Russian human cohorts |
| Clinical route | Intramuscular in registered use; the SC route is a research convention |
| Regulatory status | Registered only in Russia and the CIS; no FDA/EMA approval |
| Note | Animal origin: lot-to-lot variability |
No. Thymalin is a bovine thymus extract, a peptide mixture with no single sequence and of Soviet origin; thymosin alpha-1 is a defined synthetic 28-amino-acid peptide with approval in more than thirty countries and international clinical trials. They share the organ of origin and the immune target, not identity or evidence base.
Thymogen is the dipeptide Glu-Trp that Khavinson's group identified as one of Thymalin's active components and synthesized as a defined molecule. It is the “simplified” version of the extract; Thymalin remains the complete fraction.
Numerous Russian publications since the 1980s in secondary immunodeficiencies, recurrent infections and elderly patients, generally small cohorts lacking the rigor of modern trials, plus a 2020 pilot in COVID-19. There are no independent controlled trials outside that setting.
Because it was the first product of the Khavinson school, which holds that short peptides derived from each organ regulate gene expression in that tissue. Thymogen, Epithalon (pineal), Pinealon (nervous) and others were later derived from Thymalin. The hypothesis has limited experimental support outside the original group.
Related reading: Thymosin Alpha-1: The Thymic Immunomodulating Peptide
Informational content based on published scientific literature; it is not a recommendation for use or medical advice. Product strictly for research use (RUO), not suitable for human or veterinary consumption.
Your cart is empty